Skip to main content
Clinical Trials/NCT05926713
NCT05926713RecruitingNot Applicable

Evaluate the Effect of Dietary Supplement Combined Supervised Exercise on Physical Performance and Body Composition Among Patients With Sarcopenia and Severe Sarcopenia Comorbid With COPD or ILD: A Prospective, Multi-center Cohort Study

Orient Europharma Co., Ltd.1 site in 1 country100 target enrollmentStarted: March 1, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
100
Locations
1
Primary Endpoint
LDL-C (mg/dL)

Study Overview

Brief Summary

This trial is a prospective multi-center study. The purpose of this study is to evaluate the effect of dietary supplement combined with supervised exercised on the physical performance, body composition and lung function among patients with Sarcopenia and severe Sarcopenia in chronic lung disease. After participants enroll in this study, 12-week clinical trial will be conducted to analyze the improvement regarding Sarcopenia and different severity of Sarcopenia before and after the intervention of exercise and nutritional products, which can further provide reference for clinical intervention and rehabilitation.

Detailed Description

The design of clinical trial

This study is a prospective, multi-center, and non-invasive cohort study. All participants are diagnosed with COPD or ILD with Sarcopenia or severe Sarcopenia. The intervention consisted of providing nutritional supplements and supervised exercise for 12 weeks. After the intervention (the 12th week), the trial commissioned company provides nutritional supplements with a market price of about NT$4,000 per month for three months free to participants who are willing to continue taking the products. Those participants will be tracked for one year. The primary purpose of the study is to investigate improvement of physical performance, body composition and lung function before and after the intervention. The secondary purpose of the study is to compare the effect of the same intervention on Sarcopenia and different severity of Sarcopenia regarding the improvement of physical performance, body composition and lung function. Furthermore, the subgroup analysis is conducted to compare those who achieve the exercise requirement with those who do not concerning their physical performance, body composition and lung function.

Trail procedures

  1. Baseline demographic characteristic, health behavior and exercise habits are collected by questionnaires.
  2. The main disease diagnosis, medication, clinical assessment questionnaire or biochemical examination and radiological examination results are collected.
  3. According to the 2019 Asian Sarcopenia Consensus, participants are examined by SARC-Calf questionnaire, grip strength test and a physical performance test, including sit-stand test, short physical performance battery (SPPB), gait speed test and six-minute walk test. Afterward, bioelectrical impedance analysis (BIA) and Dual-energy X-ray absorptiometry (DXA) are applied to all participants to analyze body composition. Participants are classified into Sarcopenia group and severe Sarcopenia group.
  4. All patients receive pulmonary function test and blood test ( complete blood count, hepatic function, including [CHOL、TG、UA、SGOT、SGPT、ALK、BIL、TOTAL.BIL、DIRECT、LDH], renal function [BUN、CREAT、CA、CL、NA、K、T、P、ALB], Albumin, Vitamin D before and after the trail.
  5. All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day.
  6. All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band.
  7. The research nurse provides health education and a recording handbook for exercise and dietary record to participants before the intervention. During the intervention, the research nurse tracks participants' compliance and records the adverse reaction by telephone interview at the first week, and every other week.
  8. At the 12th week, all participants receive a comprehensive functional assessment as that at baseline after intervention to investigate the intervention effect on different severity of Sarcopenia.
  9. At the 12th week, trial commissioned manufacturer provide nutritional supplements free for 3 months. Those patients will be continuously tracked for the follow-up data for the post hoc analysis.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from Department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment.
  • Outpatients who meet the diagnostic criteria for Sarcopenia after evaluation by a physician.

Exclusion Criteria

  • Patients who refuse to sign the consent form
  • Patients who are under 20 years old
  • Patients who are bedridden or unable to walk due to physical disabilities
  • Patients with terminal cancer or human-acquired immunodeficiency syndrome
  • Patients with edema (grading pitting edema +2)

Outcomes

Primary Outcomes

LDL-C (mg/dL)

Time Frame: 12 weeks

LDL-C (mg/dL)

Total cholesterol(mg/dL)

Time Frame: 12 weeks

Hepatic function

WBC (/μL)

Time Frame: 12 weeks

Complete blood count

Change of body composition: BMI(kg/m^2)

Time Frame: 12 weeks

Change of physical performance(Sit to stand test) :SpO2%, HR, Borg score, times and second will be reported to present the result of Sit to stand test.

Time Frame: 12 weeks

SpO2%, HR, Borg score, times and second

Change of physical performance (Grip strength)

Time Frame: 12 weeks

Grip strength (kg) Instrument: Smedley dynamometer

Change of physical performance (SPPB): Sit to stand test, balance test and 4-meter walk test will be combined to report SPPB score

Time Frame: 12 weeks

Sit to stand test, balance test and 4-meter walk test will be combined to report SPPB score

Change of physical performance :6-meter walk test (second)

Time Frame: 12 weeks

5. 6-miniute walk test ( SpO2%, HR, Borg score, and the walking distance will be reported to present the result of 6-miniute walk test. )

Change of physical performance :6-miniute walk test ( SpO2%, HR, Borg score, and the walking distance will be reported to present the result of 6-miniute walk test. )

Time Frame: 12 weeks

SpO2%, HR, Borg score, and the walking distance

Change of body composition: SMI (kg/m^2)

Time Frame: 12 weeks

PBF (%), ASM (kg), LMM (kg), BMD (T-score), RASM (kg/m\^2)

BMD (T-score)

Time Frame: 12 weeks

Change of body composition

ratio of Forced Expiratory Volume in 1 second to Forced Vital Capacity as a percentage(FEV1/FVC (%))

Time Frame: 12 weeks

Change of lung function

RBC (/μL)

Time Frame: 12 weeks

Complete blood count

Hb

Time Frame: 12 weeks

Complete blood count

SGPT (U/L)

Time Frame: 12 weeks

Hepatic function

Fasting glucose (mg/dL)

Time Frame: 12 weeks

Fasting glucose (mg/dL)

HbA1c (%)

Time Frame: 12 weeks

HbA1c (%)

Total protein (g/dL)

Time Frame: 12 weeks

Total protein (g/dL)

PBF (%)

Time Frame: 12 weeks

Change of body composition

ASM (kg)

Time Frame: 12 weeks

Change of body composition

LMM (kg)

Time Frame: 12 weeks

Change of body composition

RASM (kg/m^2)

Time Frame: 12 weeks

Change of body composition

Forced Expiratory Volume in 1 second(FEV1(L))

Time Frame: 12 weeks

Change of lung function

Forced Expiratory Volume in 1 second as a percentage of predicted value(FEV1 (%))

Time Frame: 12 weeks

Change of lung function

Peak Expiratory Flow(PEF (L/min))

Time Frame: 12 weeks

Change of lung function

PLT (/μL)

Time Frame: 12 weeks

Complete blood count

Hematocrit

Time Frame: 12 weeks

Complete blood count

TG

Time Frame: 12 weeks

Hepatic function

SGOT (U/L)

Time Frame: 12 weeks

Hepatic function

Renal function

Time Frame: 12 weeks

BUN、CREAT(mg/dL)

Albumin (g/dL)

Time Frame: 12 weeks

Albumin (g/dL)

Hs-CRP

Time Frame: 12 weeks

Hs-CRP

Vitamin D

Time Frame: 12 weeks

Vitamin D

Secondary Outcomes

  • Six-minute walk test.(12 weeks)
  • Grip strength test(12 weeks)
  • SMI (kg/m^2)(12 weeks)
  • SARC-Calf questionnaire(12 weeks)
  • Bioelectrical impedance analysis (BIA)(12 weeks)
  • Forced Expiratory Volume in 1 second (FEV1)(12 weeks)
  • Peak Expiratory Flow (PEF (L/min))(12 weeks)
  • Short physical performance battery (SPPB)(12 weeks)
  • Sit-stand test(12 weeks)
  • Gait speed test(12 weeks)
  • Forced Expiratory Volume in 1 second as a percentage of predicted value (FEV1 (%))(12 weeks)
  • ratio of Forced Expiratory Volume in 1 second to Forced Vital Capacity as a percentage (FEV1/FVC (%))(12 weeks)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Evaluate the Effect of Dietary Supplement... | Clinical Trial